# VAV1

## Overview
VAV1 is a gene that encodes the vav guanine nucleotide exchange factor 1, a protein primarily involved in hematopoietic cell signaling. This protein functions as a guanine nucleotide exchange factor (GEF) for Rho family GTPases, such as Rac1, and plays a pivotal role in the regulation of cytoskeletal dynamics and immune cell activation. VAV1 is predominantly expressed in hematopoietic cells, where it is integral to T-cell receptor (TCR) signaling and the formation of the immunological synapse. The protein's structure includes several domains, such as the Dbl homology (DH) domain, pleckstrin homology (PH) domain, and Src homology domains (SH2 and SH3), which facilitate its interactions with various signaling molecules and receptors (Rapley2008Crucial; Chrencik2008Structural). VAV1's activity is modulated by phosphorylation, which is crucial for its role in immune responses and cellular signaling pathways (Yu2010Structural). Additionally, aberrations in VAV1 expression and function have been linked to several cancers, highlighting its significance in both normal cellular processes and disease states (Shalom2023Unraveling; Farago2020Vav1).

## Structure
The VAV1 protein is a guanine nucleotide exchange factor (GEF) that plays a crucial role in T-cell development and activation. It is composed of several domains, including a calponin homology (CH) domain, an acidic (Ac) region, a Dbl homology (DH) domain, a pleckstrin homology (PH) domain, a cysteine-rich domain (CRD), and Src homology 2 (SH2) and Src homology 3 (SH3) domains (Rapley2008Crucial; Yu2010Structural; Chrencik2008Structural).

The DH domain is responsible for catalyzing nucleotide exchange and is stabilized by the PH and C1 domains, which form a structural unit that enhances its activity (Rapley2008Crucial). The PH domain can bind phospholipids, influencing membrane targeting and GEF activity (Rapley2008Crucial). The CRD contains zinc finger motifs and is involved in maintaining the optimal guanine nucleotide exchange activity (Chrencik2008Structural).

VAV1's activity is regulated by phosphorylation, particularly at Tyr174, which affects the interaction with the DH domain (Yu2010Structural). The CH domain may play an autoinhibitory role by interacting with the C1 domain (Rapley2008Crucial). The protein's structure allows it to interact with multiple RhoGTPases, including Rac1, RhoA, and Cdc42, due to its unique protein-protein interaction network (Chrencik2008Structural).

## Function
The VAV1 gene encodes a protein that functions as a guanine nucleotide exchange factor (GEF) for Rho family GTPases, particularly Rac1, facilitating the exchange of GDP for GTP. This activity is crucial for the regulation of cytoskeletal rearrangement during the activation of hematopoietic cells, including T and B lymphocytes (Katzav2007Flesh). VAV1 is primarily expressed in hematopoietic cells and plays a significant role in T-cell receptor (TCR) signaling, where it is phosphorylated on tyrosine residues following TCR stimulation. This phosphorylation is essential for the activation of nuclear factor of activated T cells (NFAT), which is important for the production of interleukin-2 (IL-2) and coordinating immune responses (Katzav2007Flesh).

VAV1 also has GEF-independent functions, such as potentiating NFAT transcriptional activity and facilitating PLCγ phosphorylation (Houlard2002Vav1). It is involved in the formation of the immunological synapse, a structure that forms when a T cell interacts with an antigen-presenting cell (APC), and is necessary for the activation of integrin LFA-1, which is required for synapse formation (Katzav2007Flesh). VAV1's role in these processes is critical for proper immune system function and T-cell development (Saveliev2009Function).

## Clinical Significance
Mutations and altered expression of the VAV1 gene have been implicated in various cancers, particularly hematologic malignancies. In B-cell chronic lymphocytic leukemia (B-CLL) and B-cell non-Hodgkin's lymphoma (B-NHL), increased levels of VAV1 protein and its phosphorylated form have been observed, with overexpression more frequent in cases with 13q deletion (Farago2020Vav1). In peripheral T-cell lymphomas (PTCL) and adult T-cell leukemia/lymphoma (ATL), VAV1 mutations and gene fusions, such as VAV1-MYO1F and VAV1-S100A7, lead to increased signaling activity, contributing to T-cell transformation (Abate2017Activating; Shalom2023Unraveling).

VAV1 is also ectopically expressed in solid tumors, including lung, breast, and pancreatic cancers, where it is associated with larger tumor size, invasiveness, and poor prognosis (Lazer2009The; Farago2020Vav1). In pancreatic cancer, VAV1 promotes cell proliferation through the VAV1-Rac1-Pak1-NF-B signaling axis, enhancing cyclin D1 activity (FernandezZapico2005Ectopic). The gene's involvement in epithelial-mesenchymal transition (EMT) and interaction with the RHO/RAC GTPase signaling pathway further underscores its role in cancer progression (Shalom2023Unraveling). These findings highlight VAV1 as a potential target for therapeutic interventions in various cancers.

## Interactions
VAV1 is involved in numerous protein interactions that play critical roles in cellular signaling pathways. It interacts with receptor tyrosine kinases and co-receptors through its SH2 domain, and indirectly binds to activated receptors via adaptor proteins. In T cells, VAV1 interacts with the adaptor protein SLP76, and in B cells, it binds to BLNK (SLP65/BASH). These interactions are crucial for the phosphorylation and activation of VAV1, which is mediated by SLP76 in T cells (Turner2002VAV).

VAV1 also forms complexes with Src-family tyrosine kinases such as Lck and Fyn, and the tyrosine kinase Zap-70, which are essential for its activation through tyrosine phosphorylation. This activation leads to the reorganization of the actin cytoskeleton and stabilization of the immunological synapse (Hornstein2004Vav).

The protein interacts with heterogeneous nuclear ribonucleoprotein K (hnRNP K) and a novel 45-kDa poly(rC)-binding protein, suggesting a role in RNA biogenesis regulation (Bustelo1995Association). VAV1 also interacts with ENX-1, a putative transcriptional regulator of homeobox gene expression, indicating its involvement in transcriptional regulation (Hobert1996Interaction). 

VAV1's interactions extend to nuclear or nucleocytoplasmic shuttling partners such as Zyxin, hnRNP K, hnRNP C, and KU70, a subunit of the DNA-dependent protein kinase complex (Houlard2004Characterization). These interactions highlight VAV1's multifaceted role in cellular signaling and regulation.


## References


[1. (Hornstein2004Vav) Idit Hornstein, Andres Alcover, and Shulamit Katzav. Vav proteins, masters of the world of cytoskeleton organization. Cellular Signalling, 16(1):1–11, January 2004. URL: http://dx.doi.org/10.1016/s0898-6568(03)00110-4, doi:10.1016/s0898-6568(03)00110-4. This article has 185 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0898-6568(03)00110-4)

[2. (Houlard2002Vav1) Martin Houlard, Ramachandran Arudchandran, Fabienne Regnier-Ricard, Antonia Germani, Sylvie Gisselbrecht, Ulrich Blank, Juan Rivera, and Nadine Varin-Blank. Vav1 is a component of transcriptionally active complexes. The Journal of Experimental Medicine, 195(9):1115–1127, May 2002. URL: http://dx.doi.org/10.1084/jem.20011701, doi:10.1084/jem.20011701. This article has 65 citations.](https://doi.org/10.1084/jem.20011701)

[3. (FernandezZapico2005Ectopic) Martin E. Fernandez-Zapico, Natalia C. Gonzalez-Paz, Ellen Weiss, Doris N. Savoy, Julian R. Molina, Rafael Fonseca, Thomas C. Smyrk, Suresh T. Chari, Raul Urrutia, and Daniel D. Billadeau. Ectopic expression of vav1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell, 7(1):39–49, January 2005. URL: http://dx.doi.org/10.1016/j.ccr.2004.11.024, doi:10.1016/j.ccr.2004.11.024. This article has 181 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccr.2004.11.024)

[4. (Farago2020Vav1) Marganit Farago, Tali Yarnitzky, Batel Shalom, and Shulamit Katzav. Vav1 mutations: what makes them oncogenic? Cellular Signalling, 65:109438, January 2020. URL: http://dx.doi.org/10.1016/j.cellsig.2019.109438, doi:10.1016/j.cellsig.2019.109438. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2019.109438)

[5. (Saveliev2009Function) Alexander Saveliev, Lesley Vanes, Olga Ksionda, Jonathan Rapley, Stephen J. Smerdon, Katrin Rittinger, and Victor L. J. Tybulewicz. Function of the nucleotide exchange activity of vav1 in t cell development and activation. Science Signaling, December 2009. URL: http://dx.doi.org/10.1126/scisignal.2000420, doi:10.1126/scisignal.2000420. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2000420)

[6. (Houlard2004Characterization) Martin Houlard, Francisco Romero-Portillo, Antonia Germani, Arnaud Depaux, Fabienne Regnier-Ricard, Sylvie Gisselbrecht, and Nadine Varin-Blank. Characterization of vik-1: a new vav-interacting kruppel-like protein. Oncogene, 24(1):28–38, November 2004. URL: http://dx.doi.org/10.1038/sj.onc.1208043, doi:10.1038/sj.onc.1208043. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1208043)

[7. (Bustelo1995Association) Xosé R. Bustelo, Ki-Ling Suen, W. Matthew Michael, Gideon Dreyfuss, and Mariano Barbacid. Association of thevavproto-oncogene product with poly(rc)-specific rna-binding proteins. Molecular and Cellular Biology, 15(3):1324–1332, March 1995. URL: http://dx.doi.org/10.1128/mcb.15.3.1324, doi:10.1128/mcb.15.3.1324. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.15.3.1324)

[8. (Yu2010Structural) Bingke Yu, Ilídio R.S. Martins, Pilong Li, Gaya K. Amarasinghe, Junko Umetani, Martin E. Fernandez-Zapico, Daniel D. Billadeau, Mischa Machius, Diana R. Tomchick, and Michael K. Rosen. Structural and energetic mechanisms of cooperative autoinhibition and activation of vav1. Cell, 140(2):246–256, January 2010. URL: http://dx.doi.org/10.1016/j.cell.2009.12.033, doi:10.1016/j.cell.2009.12.033. This article has 135 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2009.12.033)

[9. (Chrencik2008Structural) Jill E. Chrencik, Alexei Brooun, Hui Zhang, Irimpan I. Mathews, Greg L. Hura, Scott A. Foster, J. Jefferson P. Perry, Markus Streiff, Paul Ramage, Hans Widmer, Gary M. Bokoch, John A. Tainer, Gisbert Weckbecker, and Peter Kuhn. Structural basis of guanine nucleotide exchange mediated by the t-cell essential vav1. Journal of Molecular Biology, 380(5):828–843, July 2008. URL: http://dx.doi.org/10.1016/j.jmb.2008.05.024, doi:10.1016/j.jmb.2008.05.024. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2008.05.024)

[10. (Rapley2008Crucial) Jonathan Rapley, Victor L J Tybulewicz, and Katrin Rittinger. Crucial structural role for the ph and c1 domains of the vav1 exchange factor. EMBO reports, 9(7):655–661, May 2008. URL: http://dx.doi.org/10.1038/embor.2008.80, doi:10.1038/embor.2008.80. This article has 65 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/embor.2008.80)

[11. (Abate2017Activating) Francesco Abate, Ana C. da Silva-Almeida, Sakellarios Zairis, Javier Robles-Valero, Lucile Couronne, Hossein Khiabanian, S. Aidan Quinn, Mi-Yeon Kim, Maria Antonella Laginestra, Christine Kim, Danilo Fiore, Govind Bhagat, Miguel Angel Piris, Elias Campo, Izidore S. Lossos, Olivier A. Bernard, Giorgio Inghirami, Stefano Pileri, Xosé R. Bustelo, Raul Rabadan, Adolfo A. Ferrando, and Teresa Palomero. Activating mutations and translocations in the guanine exchange factor vav1 in peripheral t-cell lymphomas. Proceedings of the National Academy of Sciences, 114(4):764–769, January 2017. URL: http://dx.doi.org/10.1073/pnas.1608839114, doi:10.1073/pnas.1608839114. This article has 97 citations.](https://doi.org/10.1073/pnas.1608839114)

[12. (Lazer2009The) Galit Lazer, Yulia Idelchuk, Vered Schapira, Eli Pikarsky, and Shulamit Katzav. The haematopoietic specific signal transducer vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. The Journal of Pathology, 219(1):25–34, June 2009. URL: http://dx.doi.org/10.1002/path.2579, doi:10.1002/path.2579. This article has 48 citations.](https://doi.org/10.1002/path.2579)

[13. (Shalom2023Unraveling) Batel Shalom, Yaser Salaymeh, Matan Risling, and Shulamit Katzav. Unraveling the oncogenic potential of vav1 in human cancer: lessons from mouse models. Cells, 12(9):1276, April 2023. URL: http://dx.doi.org/10.3390/cells12091276, doi:10.3390/cells12091276. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12091276)

[14. (Hobert1996Interaction) Oliver Hobert, Bahija Jallal, and Axel Ullrich. Interaction of vav with enx-1, a putative transcriptional regulator of homeobox gene expression. Molecular and Cellular Biology, 16(6):3066–3073, June 1996. URL: http://dx.doi.org/10.1128/mcb.16.6.3066, doi:10.1128/mcb.16.6.3066. This article has 104 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.6.3066)

[15. (Turner2002VAV) Martin Turner and Daniel D. Billadeau. Vav proteins as signal integrators for multi-subunit immune-recognition receptors. Nature Reviews Immunology, 2(7):476–486, July 2002. URL: http://dx.doi.org/10.1038/nri840, doi:10.1038/nri840. This article has 272 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nri840)

[16. (Katzav2007Flesh) Shulamit Katzav. Flesh and blood: the story of vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Letters, 255(2):241–254, October 2007. URL: http://dx.doi.org/10.1016/j.canlet.2007.04.015, doi:10.1016/j.canlet.2007.04.015. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2007.04.015)